Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From Jun 2019 to Jun 2024
Cardiovascular Sciences, Inc. (PINK SHEETS: CVSC) has been quite busy,
rapidly approaching a launch of its antioxidant, anti-aging cell renewal
formula and other select health related products. Initial samples of the
supplement have been delivered to the Company’s
corporate offices and have exceeded the Company’s
expectations. The supplement has also generated considerable interest
from several companies that market such products directly to physicians.
Other products complementary to the antioxidant have been delivered to
the fulfillment center.
A service agreement has been signed with United Fulfillment Solutions,
Inc. located in a large underground complex near St. Louis and products
are currently being delivered. Robert Lawrence, COO and co-owner of
UFSI, states, “We are excited that
Cardiovascular Sciences has chosen United Fulfillment as their order
fulfillment provider. Being located underground, we are able to maintain
Cardiovascular’s products in a naturally
climate controlled environment in the most eco-friendly way available.
Utilizing an underground fulfillment center to support Cardiovascular
Sciences’ distribution needs results in a
savings of over 63% on energy usage and eliminates any risk that other
centers might experience in the event of the failure of their climate
control equipment.”
Dr. Larry Hooper, CEO of Cardiovascular Sciences, Inc. explains, “We
are currently arranging and coordinating our new website with the
fulfillment center’s software and that of
various financial institutions. We expect to beta test the ordering
process within the next few days and plan a full roll out the first week
of August. Watch for press releases as we accomplish these final stages
before going live.”
About Cardiovascular Sciences
Cardiovascular Sciences, Inc. is an advanced medical device company,
with a primary focus of developing a novel technology platform to
address problems of post-surgical adhesions. Adhesions and their
complications are a significant problem worldwide for a broad range of
specialists, including general and cardiothoracic surgeons, orthopedic,
plastic, ophthalmologic and otolaryngology specialists to name a few. In
addition, the veterinary field has a tremendous need for a product that
can prevent similar problems in a variety of animals. The Company's
unique materials and processes promise a more cost-effective and
decidedly more efficient and capable means to deal with a problem that
has been so devastating to so many. Current sponsored research at the
UCF and previously at other institutions indicate that the Company is on
the right path and progressing well.
In addition to the anti-adhesion technology, the Company owns technology
in a variety of other areas, yielding a diversified portfolio with
projects in various stages of development.
Forward-looking statements in this release are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to certain risks and
uncertainties, and actual results could differ from those discussed.
This material is information only and is not an offer or solicitation to
buy or sell the securities.